FDA approves Spravato, first monotherapy nasal spray to treat depression
Jan. 21 (UPI) — The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson’s Spravato has been approved to treat a … Click to Continue »
View original article
Contributor:
